Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Kala Pharmaceuticals Inc (NQ: KALA)
10.75 USD  -0.21 (-1.92%)
Official Closing Price  /  Updated: 4:41 PM EDT, Sep 21, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 292,800
Open 10.96
Bid (Size) 10.72 (1)
Ask (Size) 14.00 (2)
Prev. Close 10.96
Today's Range 10.63 - 11.09
52wk Range 10.34 - 24.46
Shares Outstanding 24,562,400
Dividend Yield N/A
Performance
YTD
-43.36%
-43.36%
1 Month
-14.07%
-14.07%
3 Month
-21.25%
-21.25%
6 Month
-27.04%
-27.04%
1 Year
-48.04%
-48.04%
Top News
More News
Research Report Identifies Holly Energy Partners, First Merchants, Enbridge Energy Management, Activision Blizzard, Coherus BioSciences, and Kala Pharmaceuticals with Renewed Outlook — Fundamental Ana
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Holly Energy Partners, L.P.... Read More
from GlobeNewswire News Releases
Kala Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology,... Read More
from Business Wire News Releases
More News
Read More
Kala Pharmaceuticals to Present at Upcoming Investor Conferences
from Business Wire News Releases
Kala Pharmaceuticals Announces FDA Approval of INVELTYS™ for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
from Business Wire News Releases
Recent Analysis Shows Kala Pharmaceuticals, Integer, Carnival, Coty, Sykes Enterprises, and Agilent Technologies Market Influences — Renewed Outlook, Key Drivers of Growth
from GlobeNewswire News Releases
Peek Under The Hood: IWO Has 12% Upside
category ETFs
from ETF Channel
Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results
from Business Wire News Releases
Kala Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference
from Business Wire News Releases
Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease
from Business Wire News Releases
U.S. FDA approves Kala Pharma's eye pain drug
category companyNews
from Reuters: Company News
Noteworthy Thursday Option Activity: ANET, KALA, CRM
category Stocks
from Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.